麦济生物港股IPO：2024年亏损1.78亿，张江集团、康哲药业等参股

面包财经2025-08-06

近期，麦济生物向港交所主板递交上市申请，中金公司担任独家保荐人。麦济生物创立于2016年，致力于围绕过敏性及自身免疫疾病等领域未被满足的临床需求，开展创新抗体药物的自主研发及商业化工作。麦济生物构建了TEADA抗体发现平台，能高效筛选生物学活性高、成药性好的候选分子。目前，旗下靶向IL-4Rα长效抗体药物MG-K10在中重度特应性皮炎（AD）、中重度哮喘的Ⅱ期临床中，显著改善患者症状，且给药间隔...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2557340788?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-06 13:46","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2557340788","market":"hk","top_or_hot":-1,"title":"麦济生物港股IPO：2024年亏损1.78亿，张江集团、康哲药业等参股","media":"面包财经","content":"<div>\n<p>近期，麦济生物向港交所主板递交上市申请，中金公司担任独家保荐人。麦济生物创立于2016年，致力于围绕过敏性及自身免疫疾病等领域未被满足的临床需求，开展创新抗体药物的自主研发及商业化工作。麦济生物构建了TEADA抗体发现平台，能高效筛选生物学活性高、成药性好的候选分子。目前，旗下靶向IL-4Rα长效抗体药物MG-K10在中重度特应性皮炎（AD）、中重度哮喘的Ⅱ期临床中，显著改善患者症状，且给药间隔...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508061348189736d587&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>麦济生物港股IPO：2024年亏损1.78亿，张江集团、康哲药业等参股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n麦济生物港股IPO：2024年亏损1.78亿，张江集团、康哲药业等参股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-06 13:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508061348189736d587&s=b><strong>面包财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近期，麦济生物向港交所主板递交上市申请，中金公司担任独家保荐人。麦济生物创立于2016年，致力于围绕过敏性及自身免疫疾病等领域未被满足的临床需求，开展创新抗体药物的自主研发及商业化工作。麦济生物构建了TEADA抗体发现平台，能高效筛选生物学活性高、成药性好的候选分子。目前，旗下靶向IL-4Rα长效抗体药物MG-K10在中重度特应性皮炎（AD）、中重度哮喘的Ⅱ期临床中，显著改善患者症状，且给药间隔...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508061348189736d587&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999004220.SGD","symbol_name":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508061348189736d587&s=b","article_id":"2557340788","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508061348189736d587&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2557340788","pubTimestamp":1754459160,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"尚未产生收入，高额研发投入下亏损较大目前麦济生物尚未从产品销售中产生收入。2024年，公司收入2.4万元，全年研发投入1.50亿元，净亏损1.78亿元。截至2023年年底、2024年年底及2025年3月底，麦济生物流动负债分别为1.63亿元、1.78亿元及1.04亿元，主要因采购研发材料、消耗品以及应付临床开支产生大额贸易应付款项。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","00867":"康哲药业","BK1593":"医美概念股","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","HSCEI":"国企指数","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","BK1191":"制药","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","HSTECH":"恒生科技指数"},"translate_title":"Maiji Biotech Hong Kong stock IPO: Loss of 178 million in 2024, Zhangjiang Group, CMS and others will participate in shares","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1,"HSTECH":1,"HSCEI":1},"content_text":"近期，麦济生物向港交所主板递交上市申请，中金公司担任独家保荐人。麦济生物创立于2016年，致力于围绕过敏性及自身免疫疾病等领域未被满足的临床需求，开展创新抗体药物的自主研发及商业化工作。麦济生物构建了TEADA抗体发现平台，能高效筛选生物学活性高、成药性好的候选分子。目前，旗下靶向IL-4Rα长效抗体药物MG-K10在中重度特应性皮炎（AD）、中重度哮喘的Ⅱ期临床中，显著改善患者症状，且给药间隔延长至每4周一次，较有临床优势，欧美开发也在同步推进。除MG-K10外，公司还有MG-014、MG-013等多款候选产品。尚未产生收入，高额研发投入下亏损较大目前麦济生物尚未从产品销售中产生收入。2023年收入仅872.2万元，主要源于一次性技术服务，当年研发费用却高达1.66亿元，净亏损达2.53亿元。2024年，公司收入2.4万元，全年研发投入1.50亿元，净亏损1.78亿元。进入2025年，一季度未产生收入，单季研发开支2426万元，经营亏损约2727万元。从数据可以看出，公司目前研发投入较大，导致亏损不断扩大。截至2023年年底、2024年年底及2025年3月底，麦济生物流动负债分别为1.63亿元、1.78亿元及1.04亿元，主要因采购研发材料、消耗品以及应付临床开支产生大额贸易应付款项。同时，公司现金及现金等价物在2023年年底、2024年年底分别为133.8万元、253.1万元，2025年3月底为7078.5万元，资金储备相对紧张。创始人控股超四成麦济生物自成立后进行了多轮融资，最近一次为2025年5月Pre-IPO轮获2.6亿元现金注入，海南康哲药业领投1亿元，此时公司投后估值约26.4亿元。目前，张成海直接持有公司约29.24%股份，通过员工持股平台麦康克持有约13.41%股份，合计行使约42.65%的投票权，为公司实际控制人。此外，众多投资机构参股，如张江集团通过上海张江、张江燧锋持股超8%、康哲药业持股8.13%、湖南国创持股6.59%、天瑞丰年持股6.36%等。本次港股IPO，麦济生物募集资金主要用于核心产品MG-K10相关产品的研发、临床试验推进，计划推动该药剂在哮喘、慢性阻塞性肺病、慢性自发性荨麻疹等疾病的临床试验，加速研发进程，期望能将研发成果尽快推向市场，实现商业化转化。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557340788","isCrawlerRequest":true}